KLRB1 (Killer Cell Lectin Like Receptor B1)

Mechanistically, it blocks the LXR/Abca1 axis, reducing myelin lipid transfer from lipid-laden macrophages (LLMs) and downregulating T cell KLRB1, thereby augmenting T cell activation and antitumor activity. cEV@GSK enhances T cell immunity by disrupting the LXR/Abca1 axis and LLM-mediated lipid transfer, offering a novel GBM immunotherapy strategy.

We also identify a human ILC1 subset as Lin-CD127+CD161-CRTH2-CD117- (CD161- ILC1s) that can be generated from umbilical cord blood CD34+ hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.

T cell immunophenotype may be a promising predictive biomarker of vedolizumab treatment efficacy.

A decrease in their number worsens pain intensity, possibly by altering the CD4⁺/CD8⁺ T cell balance. In contrast, NK cell reductions in T cell-deficient rats may contribute to hypersensitivity in the absence of T cells.

The antigen-presenting malignant epithelial cells of ESCC exhibit significant interactions with various T cells in the TME. ICI resistance is closely associated with the crosstalk between progenitor CD8+ Tex and hyper-Treg, representing a promising target for personalized ESCC therapy.

This study evaluated the immune surveillance function in chronic myeloid leukemia (CML) through tumor antigen gene expression analysis, in vitro mixed lymphocyte cultures with peptides, and immunological analysis of patients after imatinib withdrawal to investigate factors affecting treatment-free remission (TFR)...A Cox model confirmed the prognostic value of immune markers. These results emphasize the critical role of the immune system in CML and indicate novel targets for sustaining TFR.

Docking yielded negative free energies compatible with interference in immune signaling.ConclusionsThis integrative analysis connected environmental toxicology to tumor immunity and nominated CCL19, CD40LG, IGLL5, and KLRB1 as candidate biomarkers for exposure-risk assessment. The findings are correlative and require mechanistic validation.

In vivo, RIN1 promoted the expression of IL-17 and IFN-γ in CD4+ TILs while suppressing PD-1 expression and reducing the frequency of Treg cells, exhibiting tumor growth inhibition. These findings suggested that RIN1 enhances CD4+ T cell-mediated antitumor immunity in HCC by modulating gene transcription and cell subset differentiation, highlighting its potential as an immunostimulatory agent (Graphical abstract).

The TLS/CAF-based risk model offers robust prognostic utility and highlights distinct biological and immune features between patient subgroups. These findings provide a foundation for personalized prognostic assessment and therapeutic decision-making in advanced HCC.

While limited by small tumor sample size and lack of functional assays, this study provides proof-of-concept that immune-based profiling can uncover novel prognostic markers and candidate populations of therapeutic relevance. Future work in larger, longitudinal cohorts, coupled with functional characterization, will be essential to validate these subsets and to define their role in STS immune surveillance and responsiveness to immunotherapy.

The study highlights the pivotal role of M1 macrophage-related DEGs in LUSC tumorigenesis. The newly identified 5 hub genes provide a highly accurate diagnostic tool for LUSC, offering potential improvements for both diagnostic and therapeutic strategies.

Conclusively, LLT1 expression is a promising biomarker of a favorable prognosis in gastric cancer. To our knowledge, this is the first study to demonstrate that LLT1 expression predicts improved response to combined chemotherapy and immunotherapy in gastric cancer, supporting its potential in guiding immunotherapeutic strategies.